Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00827034 · ClinicalTrials.gov registry record · Phase 1

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

A Phase 1 study of Alzheimers Disease and Huntington's Disease, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT00827034: Completed Phase 1 study of Alzheimers Disease and Huntington's Disease, sponsored by Pfizer.

NCT00827034 is a Phase 1 study of Alzheimers Disease and Huntington's Disease that has completed, run by Pfizer. The registered enrollment target is 14 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00827034, a Phase 1 study of Alzheimers Disease and Huntington's Disease, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the potential drug-drug interaction of Dimebon with the FDA-recommended CYP2C9 substrate warfarin in healthy subjects. Conformance with the guidance includes general study design using a randomized, open label, single-dose warfarin, steady-state Dimebon, 2-sequence, 2-treatment, 2-period crossover design with a minimum 7-day washout period between treatments.

Conditions Studied

Alzheimers Disease Huntington's Disease

Interventions

  • DRUG Warfarin
  • DRUG Dimebon

Study Locations (1)

Connecticut

  • Pfizer Investigational Site - New Haven

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2009-02
Est. Completion 2009-04
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT00827034 record still lists

NCT00827034 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Warfarin is the first listed.

NCT00827034 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT00827034 about?

NCT00827034 is a clinical study titled "A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects". This study will evaluate the potential drug-drug interaction of Dimebon with the FDA-recommended CYP2C9 substrate warfarin in healthy subjects. Conformance with the guidance includes general study design using a randomized, open label, single-dose warfarin, steady-state Dimebon, 2-sequence, 2-treatm...

What is the current status of trial NCT00827034?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-02. Estimated completion is 2009-04.

What conditions does trial NCT00827034 study?

This clinical trial studies the following conditions: Alzheimers Disease, Huntington's Disease.

What interventions are being tested in trial NCT00827034?

The interventions under investigation include: Warfarin (DRUG), Dimebon (DRUG).

Who is sponsoring clinical trial NCT00827034?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00827034 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00827034's enrollment target sits among peer trials

14 137th of 147 higher than 10 of 147 other Alzheimers Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00827034, the US trial registry maintained by the National Library of Medicine. NCT00827034 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.